CN107080753A - A kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body - Google Patents

A kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body Download PDF

Info

Publication number
CN107080753A
CN107080753A CN201710262736.XA CN201710262736A CN107080753A CN 107080753 A CN107080753 A CN 107080753A CN 201710262736 A CN201710262736 A CN 201710262736A CN 107080753 A CN107080753 A CN 107080753A
Authority
CN
China
Prior art keywords
excretion body
mesenchymal stem
cosmetic formulation
umbilical cord
culture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201710262736.XA
Other languages
Chinese (zh)
Inventor
钱开诚
张涤平
刘家权
鲁立
聂燕华
陈贤光
梅杰
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Orchid Pavilion Science And Technology Co Ltd
SHENZHEN CELL TECHNOLOGY Co Ltd
Original Assignee
Shenzhen Orchid Pavilion Science And Technology Co Ltd
SHENZHEN CELL TECHNOLOGY Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Orchid Pavilion Science And Technology Co Ltd, SHENZHEN CELL TECHNOLOGY Co Ltd filed Critical Shenzhen Orchid Pavilion Science And Technology Co Ltd
Priority to CN201710262736.XA priority Critical patent/CN107080753A/en
Publication of CN107080753A publication Critical patent/CN107080753A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/886—Aloeaceae (Aloe family), e.g. aloe vera
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/34—Alcohols
    • A61K8/345—Alcohols containing more than one hydroxy group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations

Abstract

The invention belongs to biomedicine field, and in particular to a kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body, and the preparation includes following component：Human mesenchymal stem cell source excretion body freeze-dried powder, glycerine, asparagus juice；The weight ratio of three is 1:1:10‑20；The preparation method of the preparation is：The human mesenchymal stem cell source excretion body freeze-dried powder, glycerine, asparagus juice are weighed in proportion, mixes to transparent, and then the filtering with microporous membrane through 0.45 μm, 0.22 μm successively, that is, obtain the cosmetic formulation.The present invention as active component, can be prepared a kind of cosmetic formulation for having a positive effect, can solve the problems, such as the skin aging of people using a kind of new human mesenchymal stem cell source excretion body；With great market prospects and application value.

Description

A kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body
Technical field
The invention belongs to biomedicine field, and in particular to a kind of beauty system of human umbilical cord mesenchymal stem cells source excretion body Agent.
Background technology
2013, the regulation mechanism for the cell vesicle transport that the U.S., 3 scientists of Germany are had found by them was won Nobel prize's soul.Excretion body (exosomes) is also begun to by increasingly as the important vesica of a class in human body Many concerns.Scientists have found that excretion, which is known from experience, participates in immune response, apoptosis, angiogenesis, inflammatory reaction, condensation etc. In important bioprocess, some signaling molecules can be secreted into tissue or cell farther out by cell by secreting excretion body, To play regulating and controlling effect.
2016, Jiangsu Province, China University Medical College was permitted literary honor et al. research discovery, human umbilical cord mesenchymal stem cells source excretion The protein that body is included, can be cooperated with the signaling molecule during skin regeneration.(document：Zhang,B.,et al. (2016)."HucMSC Exosome-Delivered 14-3-3zeta Orchestrates Self-control of the Wnt Response via Modulation of YAP during Cutaneous Regeneration."Stem Cells.) first, the effect of rat deepⅱdegreeburn, finder are treated by assessing human umbilical cord mesenchymal stem cells source excretion body Umbilical cord mesenchymal stem cells source excretion body promotes self adjusting for Wnt/ β-catenin signal paths in the regeneration remodelling phase of skin Section.Secondly, the proteome analysis of human umbilical cord mesenchymal stem cells source excretion body shows, relevant albumen can pass through excretion body Transport.Comprehensive research result shows that human umbilical cord mesenchymal stem cells source excretion body can not only be used as Wnt/ β-catenin signals " accelerator " can control skin regeneration to be used as the signal to promote the Regeneration and Repair of damaged skin tissue by adjusting YAP " brake ".
Therefore, in terms of aging skin/damaged skin is repaired, with wide market prospects, but the production in the field at present Product anti-aging effects are unsatisfactory, and finding a kind of anti-aging, good product is the very urgent thing in the current field.
The content of the invention
Therefore, the technical problems to be solved by the invention are the clear area for overcoming prior art, so as to propose a kind of anti- The cosmetic formulation of the good human umbilical cord mesenchymal stem cells source excretion body of aging effects.
In order to solve the above technical problems, the invention discloses a kind of beauty system of human umbilical cord mesenchymal stem cells source excretion body Agent, the preparation includes following component：Human mesenchymal stem cell source excretion body freeze-dried powder, glycerine, asparagus juice；The weight ratio of three For 1:1:10-20.
It is preferred that, the preparation method of the preparation is：The human mesenchymal stem cell source excretion body is weighed in proportion to freeze Powder, glycerine, asparagus juice, mix to transparent, and then the filtering with microporous membrane through 0.45 μm, 0.22 μm successively, that is, obtain institute State cosmetic formulation.
It is preferred that, the outer membrane of the excretion body is to contain micro-RNA, institute inside phophoslipid bilayer structure, the excretion body State at least one of mRNA, DNA and nucleic acid of excretion body source cell.
It is preferred that, the acquisition methods of described excretion body are as follows：
A) human mesenchymal stem cell is cultivated, cultivation stage added in cell culture medium interferon, EPO and PDGF-BB；
B) stem cell after culture is pre-processed；
C) the human umbilical cord mesenchymal stem cells source excretion body is extracted in the supernatant of culture medium after the pre-treatment.
It is preferred that, in the asparagus juice, containing aloe polysaccharide, content is 700-800mg/L.
It is preferred that, the excretion body differentiates for MSC.
It is preferred that, the mescenchymal stem cell is human umbilical cord mesenchymal stem cells.
It is preferred that, the pretreatment is concretely comprised the following steps：
1) people's passage MSC is subjected to serum free suspension culture, and it is 1.0 × 10 to adjust cell concentration6/ml；
2) according to 106The big culture dish inoculations of/150mm, are cultivated to cell fusion degree to 70-80%, incubation time is 2-3 My god；
3) liquid in culture dish is absorbed, and culture dish is washed with alpha-MEM fluid nutrient mediums；
4) 20ml alpha-MEM is added again in 150mm culture dishes；
5) recombinant human interferon alpha 2, PDGF-BB and EPO are sequentially added；
7) at 37 DEG C, 5% CO2Under the conditions of cultivate 96 hours, collection obtain MSC nutrient solutions.
It is preferred that, the concentration of interferon is that 10U/ml~600U/ml, PDGF-BB concentration are in the MSC nutrient solutions 2ng/ml~60ng/ml, EPO concentration are 0.1IU/ml~5IU/ml.
It is preferred that, the step 2) pretreatment be specially：
1) supernatant of the MSC nutrient solutions is taken, centrifugal treating is carried out, cell fragment is removed；
2) and then by supernatant membrane filtration handle, remove apoptotic body, obtain pretreated supernatant.
It is preferred that, the step 3) be specially：
1) centrifuge tube of the product of trying to please for 5 parts by volume, adds the excretion body separation agent of 1 parts by volume；
2) the pretreated supernatant of process of 4 parts by volume is added, is fully mixed；
3) after stewing process, then centrifugal treating twice is carried out, obtains the excretion body.
The above-mentioned technical proposal of the present invention has advantages below compared with prior art：The present invention uses a kind of new human world Mesenchymal stem cells source excretion body can prepare a kind of cosmetic formulation for having a positive effect as active component, can be in solution The certainly skin aging problem of people；Preparation method is easy, be adapted to it is instant match somebody with somebody, the bioactive ingredients of excretion body are utilized well； Prepare cost relatively low, be adapted to be used for multiple times, user can be allowed to keep cosmetic result for a long time；Material used is by national medicine The pharmaceutic adjuvant of prison department approval, can reduce side effect, it is ensured that the skin safe of user；With great market prospects and Application value.
Embodiment
Present embodiment discloses a kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body, the system for embodiment 1 Agent includes following component：Human mesenchymal stem cell source excretion body freeze-dried powder, glycerine, asparagus juice；The weight ratio of three is 1:1:15； In the asparagus juice, containing aloe polysaccharide, content is 750mg/L.
The preparation method of the preparation is：Weigh in proportion the human mesenchymal stem cell source excretion body freeze-dried powder, glycerine, Asparagus juice, mixes to transparent, and then the filtering with microporous membrane through 0.45 μm, 0.22 μm successively, that is, obtain the beauty system Agent.
Present embodiment discloses a kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body, the system for embodiment 2 Agent includes following component：Human mesenchymal stem cell source excretion body freeze-dried powder, glycerine, asparagus juice；The weight ratio of three is 1:1:10； In the asparagus juice, containing aloe polysaccharide, content is 800mg/L.
The preparation method of the preparation is：Weigh in proportion the human mesenchymal stem cell source excretion body freeze-dried powder, glycerine, Asparagus juice, mixes to transparent, and then the filtering with microporous membrane through 0.45 μm, 0.22 μm successively, that is, obtain the beauty system Agent.
Present embodiment discloses a kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body, the system for embodiment 3 Agent includes following component：Human mesenchymal stem cell source excretion body freeze-dried powder, glycerine, asparagus juice；The weight ratio of three is 1:1:20； In the asparagus juice, containing aloe polysaccharide, content is 700mg/L.
The preparation method of the preparation is：Weigh in proportion the human mesenchymal stem cell source excretion body freeze-dried powder, glycerine, Asparagus juice, mixes to transparent, and then the filtering with microporous membrane through 0.45 μm, 0.22 μm successively, that is, obtain the beauty system Agent.
The acquisition methods of excretion body mentioned in the embodiment 1 of embodiment 4 are as follows：
A. people MSC culture and pretreatment
1. material and reagent
1) people's umbilical cord, placenta, marrow, the MSC in fatty or other sources, passage number is within 6 generations.
2) people MSC serum free mediums
3)alpha-MEM
4) recombinant human interferon alpha 2
5) recombinant human epo
6) rhPDGF-BB-BB
7) culture dish (diameter 150mm)
8) other consumptive materials
2. cell culture
1) it will count, suspended using MSC Serum-free complete mediums, adjustment cell concentration is 1.0 after people's passage MSC digestion ×106/ml。
2) according to 106The big culture dish inoculations of/150mm, culture to cell fusion degree to 70-80%.Generally require 2-3 days.
3) liquid in culture dish is absorbed, and culture dish is washed with alpha-MEM fluid nutrient mediums.
4) alpha-MEM 20ml/150mm culture dishes are added.
5) recombinant human interferon alpha 2, PDGF-BB are firstly added, in 37 DEG C, 5% CO2Under the conditions of cultivate 24 hours；Then, EPO is added, in 37 DEG C, 5% CO2Under the conditions of cultivate 72 hours.
Recombinant human interferon alpha 2 (final concentration of 10U/ml~600U/ml), PDGF-BB (2ng/ml~60ng/ml) and EPO (0.1IU/ml~5IU/ml).
7) 37 DEG C, 5%CO2Under the conditions of cultivate 96 hours.
8) collect supernatant and carry out following handle.It such as can not in time handle, supernatant is placed in -80 DEG C of preservations.
B. the pretreatment of people MSC culture supernatants
1. material and reagent
1) consumptive material such as centrifuge tube.
2) aperture is 1 μm, 0.45 μm and 0.22 μm of filter.
2. operating procedure
1) collect and centrifuge 2000g under the conditions of cells and supernatant, room temperature or 4 DEG C, 10 minutes, remove cell fragment.
2) by culture supernatant or body fluid respectively through a diameter of 1 μm, 0.45 μm and 0.22 μm membrane filtration, to remove wherein Apoptotic body that may be present.
C. the harvest of excretion body
1) 50ml centrifuge tubes are taken, excretion body separation agent 10ml is added.Or 250ml centrifuge tubes are taken, add excretion body reagent 50ml。
2) treated cells and supernatant 40ml is added, is fully mixed.Or add culture supernatant 200ml.
3) 4 DEG C are placed in overnight, or at least 6 hours.
4) centrifuge, 2000g, 30 minutes.
5) liquid is removed, is centrifuged again, 2000g, 5 minutes.
6) residual liquid is carefully absorbed with pipette.
7) the PBS or μ l to 1ml of physiological saline 500 is added.Or add PBS or physiological saline 2.5ml to 5ml.
8) protein concentration is determined, or carries out the Instrumental Analysis such as flow cyctometry.
D. prepared by the freeze-dried powder of gained excretion body
Gained excretion body is taken, mannitol (1%~15%) is added, mixed, is filtered (0.22 μm), packing, then be positioned over super Low temperature refrigerator (- 80 DEG C) 10h.Then, lyophilized (- 50 DEG C, 24h) are carried out under 10Pa vacuum, obtains human mesenchyme dry thin Born of the same parents source excretion body freeze-dried powder.
Experimental example
First, stability test
Gained cosmetic formulation is preserved under the conditions of being positioned over -20 DEG C.Observed after six months, no significant change.
2nd, validity test
Ten Mies are selected in beauty parlor, are divided into two groups, one of which tries out gained cosmetic formulation, and another group using conventional Cosmetics.After a course for the treatment of (30 days) is completed, assay result is listed in table 1, table 2.
Feel and sensory evaluation after the use of the excretion body cosmetic formulation of table 1 group on probation
Sequence number Skin type and situation Sex Age bracket It is invalid Typically Well It is effective
01 Oiliness microgroove Female 30~35 √
02 Neutrality wrinkle Female 40~45 √
03 Neutral spot Female 25~30 √
04 Dryness microgroove Female 25~30 √
05 Dryness wrinkle spot Female 40~45 √
Feel and sensory evaluation after the use of the conventional cosmetic preparations. Control group of table 2
Sequence number Skin type and situation Sex Age bracket It is invalid Typically Well It is effective
01 Oiliness microgroove Female 30~35 √
02 Neutrality wrinkle Female 40~45 √
03 Neutral spot Female 25~30 √
04 Dryness microgroove Female 25~30 √
05 Dryness wrinkle spot Female 40~45 √
Consolidated statement 1, the result of table 2 are it can be found that the cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body, for each The skin of type has good or effective effect.And compared to conventional cosmetic preparation, human umbilical cord mesenchymal stem cells The cosmetic formulation of source excretion body has more preferable effect for the skin problem of neutral wrinkle and dryness wrinkle spot, and can releive ladies face To wrinkle problem.
Obviously, above-described embodiment is only intended to clearly illustrate example, and the not restriction to embodiment.It is right For those of ordinary skill in the art, can also make on the basis of the above description it is other it is various forms of change or Change.There is no necessity and possibility to exhaust all the enbodiments.And the obvious change thus extended out or Among changing still in the protection domain of the invention.

Claims (10)

1. a kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body, it is characterised in that the preparation includes such as the following group Point：Human mesenchymal stem cell source excretion body freeze-dried powder, glycerine, asparagus juice；The weight ratio of three is 1:1:10-20.
2. cosmetic formulation as claimed in claim 1, it is characterised in that the preparation method of the preparation is：Institute is weighed in proportion State human mesenchymal stem cell source excretion body freeze-dried powder, glycerine, asparagus juice, mix to it is transparent, then successively through 0.45 μm, 0.22 μm of filtering with microporous membrane, that is, obtain the cosmetic formulation.
3. cosmetic formulation as claimed in claim 1 or 2, it is characterised in that the outer membrane of the excretion body is phophoslipid bilayer structure, Contain at least one of micro-RNA, mRNA, DNA of the excretion body source cell and nucleic acid inside the excretion body.
4. cosmetic formulation as claimed in claim 3, it is characterised in that the acquisition methods of described excretion body are as follows：
A) human mesenchymal stem cell is cultivated, cultivation stage adds interferon, EPO and PDGF-BB in cell culture medium；
B) stem cell after culture is pre-processed；
C) the human umbilical cord mesenchymal stem cells source excretion body is extracted in the supernatant of culture medium after the pre-treatment.
5. the acquisition methods of excretion body as claimed in claim 4, it is characterised in that in the asparagus juice, containing aloe polysaccharide, Content is 700-800mg/L.
6. the acquisition methods of excretion body as claimed in claim 5, it is characterised in that between the mescenchymal stem cell behaviour umbilical cord Mesenchymal stem cells；The excretion body differentiates for MSC.
7. the acquisition methods of excretion body as claimed in claim 6, it is characterised in that the specific steps of the pretreatment For：
1) people's passage MSC is subjected to serum free suspension culture, and it is 1.0 × 10 to adjust cell concentration6/ml；
2) according to 106The big culture dish inoculations of/150mm, culture to cell fusion degree to 70-80%, incubation time is 2-3 days；
3) liquid in culture dish is absorbed, and culture dish is washed with alpha-MEM fluid nutrient mediums；
4) 20ml alpha-MEM is added again in 150mm culture dishes；
5) recombinant human interferon alpha 2, PDGF-BB and EPO are sequentially added；
7) at 37 DEG C, 5% CO2Under the conditions of cultivate 96 hours, collection obtain MSC nutrient solutions.
8. the acquisition methods of excretion body as claimed in claim 7, it is characterised in that interferon is dense in the MSC nutrient solutions Degree is that 10U/ml~600U/ml, PDGF-BB concentration are 2ng/ml~60ng/ml, and EPO concentration is 0.1IU/ml~5IU/ ml。
9. the acquisition methods of excretion body as claimed in claim 8, it is characterised in that the step 2) pretreatment it is specific For：
1) supernatant of the MSC nutrient solutions is taken, centrifugal treating is carried out, cell fragment is removed；
2) and then by supernatant membrane filtration handle, remove apoptotic body, obtain pretreated supernatant.
10. the acquisition methods of excretion body as claimed in claim 9, it is characterised in that the step 3) be specially：
1) centrifuge tube of the product of trying to please for 5 parts by volume, adds the excretion body separation agent of 1 parts by volume；
2) the pretreated supernatant of process of 4 parts by volume is added, is fully mixed；
3) after stewing process, then centrifugal treating twice is carried out, obtains the excretion body.
CN201710262736.XA 2017-04-20 2017-04-20 A kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body Withdrawn CN107080753A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201710262736.XA CN107080753A (en) 2017-04-20 2017-04-20 A kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201710262736.XA CN107080753A (en) 2017-04-20 2017-04-20 A kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body

Publications (1)

Publication Number Publication Date
CN107080753A true CN107080753A (en) 2017-08-22

Family

ID=59612817

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201710262736.XA Withdrawn CN107080753A (en) 2017-04-20 2017-04-20 A kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body

Country Status (1)

Country Link
CN (1) CN107080753A (en)

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108823159A (en) * 2018-07-13 2018-11-16 李璇 The influence for the excretion body that PDGF-BB discharges mescenchymal stem cell
CN109865033A (en) * 2019-03-21 2019-06-11 北京隆祺生物科技有限公司 A kind of external application medical ointment and its application in reparation diabetes wound
CN110403898A (en) * 2019-09-06 2019-11-05 天津珂芬迪斯生物医药科技有限公司 A kind of jelly peptide facial mask and preparation method thereof
CN111544369A (en) * 2020-05-25 2020-08-18 和携科技有限公司 A facial skin caring composition and its preparation method
CN113208998A (en) * 2021-05-11 2021-08-06 奥启(深圳)创投科技有限公司 Anti-wrinkle essence containing stem cell exosomes
CN113249316A (en) * 2021-06-16 2021-08-13 基因组诊断有限公司 Preparation method and application of umbilical cord/placenta mesenchymal stem cell-derived exosome
CN113662905A (en) * 2021-08-19 2021-11-19 蓝海细胞(北京)生物科技有限公司 Preparation method of stem cell exosome facial mask liquid
CN114349856A (en) * 2022-03-11 2022-04-15 诺赛联合(北京)生物医学科技有限公司 Fibroblast outer capsule preparation and application thereof in cosmetics and medicines
CN114736296A (en) * 2022-03-11 2022-07-12 诺赛联合(北京)生物医学科技有限公司 Medicine or cosmetic prepared from fibroblast outer vesicle

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105477016A (en) * 2015-11-13 2016-04-13 中国人民解放军第二军医大学 Application of exosome derived from human mesenchymal stem cells to resistance to tissue fibrosis and scar forming
WO2017023690A1 (en) * 2015-07-31 2017-02-09 Exoceuticals, Inc. Exosome compositions and methods for preparation and use thereof for regulating and conditioning skin and hair

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017023690A1 (en) * 2015-07-31 2017-02-09 Exoceuticals, Inc. Exosome compositions and methods for preparation and use thereof for regulating and conditioning skin and hair
CN105477016A (en) * 2015-11-13 2016-04-13 中国人民解放军第二军医大学 Application of exosome derived from human mesenchymal stem cells to resistance to tissue fibrosis and scar forming

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOYDEEP BASU ET AL: "Exosomes for Repair, Regeneration and Rejuvenation", 《EXPERT OPINION ON BIOLOGICAL THERAPY》 *
国家食品药品监督管理总局: "化妆品安全技术规范", 《化妆品安全技术规范》 *
张霞: "芦荟美容的生物学原理", 《湖南教育学院学报》 *

Cited By (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108823159A (en) * 2018-07-13 2018-11-16 李璇 The influence for the excretion body that PDGF-BB discharges mescenchymal stem cell
CN108823159B (en) * 2018-07-13 2022-08-09 上海齐昔生物科技集团有限公司 Effect of PDGF-BB on exosomes released by mesenchymal Stem cells
CN109865033A (en) * 2019-03-21 2019-06-11 北京隆祺生物科技有限公司 A kind of external application medical ointment and its application in reparation diabetes wound
CN110403898A (en) * 2019-09-06 2019-11-05 天津珂芬迪斯生物医药科技有限公司 A kind of jelly peptide facial mask and preparation method thereof
CN111544369B (en) * 2020-05-25 2022-04-29 和携科技有限公司 A facial skin caring composition and its preparation method
CN111544369A (en) * 2020-05-25 2020-08-18 和携科技有限公司 A facial skin caring composition and its preparation method
CN113208998A (en) * 2021-05-11 2021-08-06 奥启(深圳)创投科技有限公司 Anti-wrinkle essence containing stem cell exosomes
CN113249316A (en) * 2021-06-16 2021-08-13 基因组诊断有限公司 Preparation method and application of umbilical cord/placenta mesenchymal stem cell-derived exosome
CN113662905A (en) * 2021-08-19 2021-11-19 蓝海细胞(北京)生物科技有限公司 Preparation method of stem cell exosome facial mask liquid
CN114349856B (en) * 2022-03-11 2022-05-17 诺赛联合(北京)生物医学科技有限公司 Fibroblast outer capsule infusion preparation and application thereof in beauty treatment and medicines
CN114736296A (en) * 2022-03-11 2022-07-12 诺赛联合(北京)生物医学科技有限公司 Medicine or cosmetic prepared from fibroblast outer vesicle
CN114349856A (en) * 2022-03-11 2022-04-15 诺赛联合(北京)生物医学科技有限公司 Fibroblast outer capsule preparation and application thereof in cosmetics and medicines
CN114736296B (en) * 2022-03-11 2022-11-08 诺赛联合(北京)生物医学科技有限公司 Antibody and application thereof in promoting skin fibroblast proliferation

Similar Documents

Publication Publication Date Title
CN107080753A (en) A kind of cosmetic formulation of human umbilical cord mesenchymal stem cells source excretion body
CN106109496B (en) Human umbilical cord mesenchymal stem cells extract freeze-drying powder and preparation method
US20230364150A1 (en) Method for isolation and purification of microvesicles from cell culture supernatants and biological fluids
CN107245472B (en) Preparation method and use method of human mesenchymal stem cell exosome freeze-dried powder
ES2373551T3 (en) METHODS FOR USING CELLS DERIVED FROM ADIPOSE TISSUE IN THE TREATMENT OF CARDIOVASCULAR AFFECTIONS.
CN108721200A (en) A kind of preparation method and application of the excretion body cosmetic formulation in human mesenchymal stem cell source
CN108633877A (en) A kind of human umbilical cord mesenchymal stem cells excretion body freeze-dried powder and its method of preparation
CN106176563B (en) People's umbilical cord MSC serum-free medium lipidosome freeze-dried powder and its preparation and application
CN106913583A (en) The preparation method and application of human mesenchymal stem cell source excretion body biologically active agents
CN108348555B (en) Cell expansion methods and therapeutic compositions
JP2010538681A (en) Methods for extracting mesenchymal stem cells from human or animal embryos and their secretions
CN104694466A (en) Preparation of mesenchymal stem cells (MSCs) derived exosomes and application of the same in acute lung injury
CN107006452A (en) A kind of human umbilical cord mesenchymal stem cells source excretion body freezes store method and its application
CN113197919B (en) Application of pilose antler stem cell exosome in preparing product for improving or treating osteoarthritis and delaying cell senescence
CN110195038A (en) A kind of preparation method improving mescenchymal stem cell excretion body yield
CN107410288B (en) Storage liquid of human umbilical cord mesenchymal stem cells
CN112111451A (en) Method for increasing yield of stem cell cytokines
RU2574017C1 (en) Medication for treating burns and wounds based on cytokines and growth factors, secreted by mesenchymal human cells, method for thereof obtaining and method for treating burns and wounds
CN106566803A (en) Culture solution, application of culture solution and method for culturing umbilical cord mesenchymal stem cells
Pu et al. Injectable human decellularized adipose tissue hydrogel containing stem cells enhances wound healing in mouse
CN113425619B (en) Purification preparation method and application of mesenchymal stem cell secretion factor
CN110237026A (en) A kind of Sodium Hyaluronate compound fat stem cell conditioned medium lyophilized preparation
Lamblet et al. Fat obtained from plastic surgery procedures—stem cells derived from adipose tissue and their potential in technological innovation: a narrative literature review and perspective on dissociative methods
KR102161946B1 (en) Paracrine factor and preparation thereof
KR102161947B1 (en) A composition for culture of cells comprising paracrine factor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20170822